Shares of Sanara MedTech Inc. (NASDAQ:SMTI - Get Free Report) were up 1.5% during trading on Friday . The stock traded as high as $33.63 and last traded at $33.51. Approximately 15,305 shares were traded during trading, a decline of 20% from the average daily volume of 19,089 shares. The stock had previously closed at $33.00.
The company has a debt-to-equity ratio of 0.35, a current ratio of 1.80 and a quick ratio of 1.49. The stock has a market capitalization of $293.11 million, a price-to-earnings ratio of -42.96 and a beta of 1.58. The business has a fifty day moving average of $32.41 and a 200 day moving average of $31.15.
Sanara MedTech (NASDAQ:SMTI - Get Free Report) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.41) earnings per share (EPS) for the quarter. Sanara MedTech had a negative return on equity of 15.17% and a negative net margin of 9.07%. The business had revenue of $20.16 million for the quarter. As a group, equities analysts predict that Sanara MedTech Inc. will post -2.03 earnings per share for the current year.
A hedge fund recently raised its stake in Sanara MedTech stock. Price T Rowe Associates Inc. MD increased its stake in shares of Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) by 5.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,805 shares of the company's stock after purchasing an additional 322 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.07% of Sanara MedTech worth $215,000 at the end of the most recent quarter. 8.10% of the stock is owned by institutional investors and hedge funds.
Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sanara MedTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanara MedTech wasn't on the list.
While Sanara MedTech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.